EPZ-5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ-5676 is a SAM-competitive, highly selective DOT1L histone methyltransferase inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, outperforming other methyltransferase inhibitors in selectivity and efficacy (product page). It induces potent cytotoxicity in MLL-rearranged leukemia cell lines by blocking H3K79 methylation and downregulating MLL-fusion target genes (Anichini et al., 2022). In vivo, EPZ-5676 achieves complete tumor regression in MV4-11 xenografts at 35–70 mg/kg/day over 21 days, with minimal toxicity. Its >37,000-fold selectivity over related methyltransferases (CARM1, EZH2, PRMT family, etc.) reduces off-target effects. This profile positions EPZ-5676 as a gold-standard research reagent and candidate for epigenetic intervention in acute leukemias.

Biological Rationale

DOT1L (Disruptor of telomeric silencing 1-like) is the only known histone methyltransferase that methylates lysine 79 on histone H3 (H3K79). Methylation of H3K79 is associated with active gene transcription. In mixed-lineage leukemia (MLL)-rearranged leukemias, MLL fusion proteins aberrantly recruit DOT1L, causing increased H3K79 methylation and upregulation of leukemogenic gene programs (Anichini et al., 2022). Inhibition of DOT1L selectively disrupts this pathological transcriptional landscape, making it a critical target for epigenetic therapy in MLL-rearranged leukemias. Several studies have highlighted the unique role of DOT1L in leukemogenesis, distinguishing it from other methyltransferases that target distinct histone residues or mediate gene repression.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ-5676 (A4166) is a small molecule that selectively and potently inhibits DOT1L by competitively binding to the S-adenosyl methionine (SAM) pocket. This binding induces conformational changes in DOT1L, opening a hydrophobic pocket beyond the amino acid moiety of SAM (product page). The inhibition is highly specific, with an IC₅₀ of 0.8 nM and a Ki of 80 pM for DOT1L, and minimal activity against other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. By blocking DOT1L-mediated H3K79 methylation, EPZ-5676 downregulates MLL-fusion target genes, leading to apoptosis and inhibition of proliferation in MLL-rearranged leukemia cells. In contrast, non-MLL-translocated cells show minimal response, underscoring the selectivity of the mechanism (see detailed mechanistic review—this article clarifies the molecular specificity compared to prior mechanistic overviews).

Evidence & Benchmarks

• EPZ-5676 inhibits DOT1L with an in vitro IC₅₀ of 0.8 nM and a Ki of 80 pM under enzyme assay conditions (50 mM Tris, pH 8.0, 5 mM DTT, 0.01% Tween-20, 30°C) (ApexBio datasheet).
• It exhibits >37,000-fold selectivity over other histone methyltransferases, including CARM1 and EZH2, in side-by-side enzymatic assays (Anichini et al., 2022, DOI).
• In MV4-11 acute leukemia cells, EPZ-5676 inhibits proliferation with an IC₅₀ of 3.5 nM after 4–7 days of continuous treatment (ApexBio, datasheet).
• In nude rat xenograft models, daily intravenous administration of 35–70 mg/kg for 21 days results in complete tumor regression and is well tolerated, with no significant weight loss (Anichini et al., 2022, DOI).
• EPZ-5676 suppresses H3K79 methylation and downregulates MLL-fusion target gene expression as confirmed by western blot and gene expression assays (Anichini et al., 2022).
• Compared to other epigenetic inhibitors, such as guadecitabine (DNMT inhibitor) or GSK126 (EZH2 inhibitor), EPZ-5676 demonstrates a unique specificity profile and limited immune-related gene upregulation (DOI, Fig. 2–3).

Applications, Limits & Misconceptions

EPZ-5676 is primarily deployed in biochemical enzyme inhibition assays, cell proliferation studies, and in vivo leukemia models. Its nanomolar potency and high selectivity make it an essential tool for dissecting DOT1L-dependent pathways in cancer research. As summarized in this related review (which this article updates with expanded in vivo benchmarks), EPZ-5676 enables precision modulation of epigenetic marks relevant to MLL-rearranged leukemia.

However, its efficacy is largely limited to MLL-rearranged leukemias. Non-MLL-fusion cancers and non-transformed cells do not exhibit the same sensitivity. Moreover, unlike DNMT or HDAC inhibitors, EPZ-5676 does not broadly activate immune-related gene signatures (DOI, Table 1).

Common Pitfalls or Misconceptions

• EPZ-5676 is not a pan-methyltransferase inhibitor: It is highly selective for DOT1L and ineffective against DNMTs, EZH2, and PRMT family members (DOI).
• Limited efficacy outside MLL-rearranged leukemia: Non-MLL-translocated cells show minimal cytotoxic response.
• No broad immune gene activation: Unlike DNMT inhibitors, EPZ-5676 does not significantly upregulate immune-related genes in solid tumor models.
• Water insolubility: EPZ-5676 is insoluble in water and should be prepared in DMSO or ethanol for biochemical assays (datasheet).
• Stability issues: Stock solutions must be stored at -20°C, and long-term storage of solutions is discouraged to prevent degradation.

Workflow Integration & Parameters

EPZ-5676 is supplied as a solid (molecular weight 562.71) and is soluble at ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (with ultrasound). It is insoluble in water (product page). For enzymatic or cell-based assays, solutions should be freshly prepared and stored at -20°C for short periods. Recommended working concentrations are in the 1–10 nM range for biochemical assays and 3–10 nM for cell proliferation studies, particularly in MV4-11 or similar MLL-rearranged leukemia cell lines. In vivo, studies have used 35–70 mg/kg/day via intravenous administration for 21 days without significant toxicity. Standard controls include parallel testing with non-MLL-translocated cells to confirm selectivity (see this interlinked article for translational workflow guidance; this page expands on workflow optimization for reagent handling and dosing).

Conclusion & Outlook

EPZ-5676 stands as a benchmark DOT1L inhibitor, offering unmatched potency and selectivity for mechanistic and translational research in MLL-rearranged leukemia. Its nanomolar inhibitory activity and well-characterized selectivity profile enable precise interrogation of DOT1L-dependent epigenetic regulation. While its utility is primarily in MLL-rearranged leukemias, EPZ-5676 remains a foundational tool for both basic and preclinical research into histone methylation and gene regulation. For further mechanistic context, readers are encouraged to consult this review, which this article extends by providing updated benchmarks and workflow standards. For ordering or technical specifications, visit the DOT1L inhibitor EPZ-5676 (A4166) product page.